The Patient’s Perspective on Psoriatic Arthritis: What More Can Rheumatologists Do to Optimise Disease Management?
This symposium took place on 16th June 2017 as a part of the European League Against Rheumatism (EULAR) Congress in Madrid, Spain
Speakers: Juan Gomez-Reino,1 Ana-Maria Orbai,2 Laure Gossec3
1. Hospital Clinico Universitario de Santiago, La Coruña, Spain
2. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
3. Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique (UMRS 1136); Rheumatology Department, Hôpital Pitié Salpêtrière, AP-HP, Paris, France
Disclosure: Prof Juan Gomez-Reino has served on advisory boards for AbbVie, Biogen, Bristol-Myers Squibb, Lilly, Pfizer, Roche, R-Pharma, Sanofi, and Regeneron; has been a part of a speaker’s bureau for AbbVie, Bristol-Myers Squibb, Janssen, MSD, Pfizer, Roche, and Sanofi; has received grants from MSD, Pfizer, Roche, and UCB. Dr Ana-Maria Orbai has served on advisory boards for Janssen, Eli Lilly, and UCB, as a consultant for Janssen and Pfizer; has been a part of clinical trials as an investigator for Lilly and Novartis. Prof Laure Gossec has received research grants from UCB, Lilly, Pfizer, and Bristol-Myers Squibb; has received consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, and UCB; and is a board member of the Executive Committees of EULAR and OMERACT.
Acknowledgements: Writing assistance was provided by Alessandra Bittante, ApotheCom, London, UK.
Support: The publication of this article was funded by Pfizer. The views and opinions expressed are those of the speakers and not necessarily Pfizer.
Citation: EMJ Rheumatol. 2017;4:50-57.
The symposium at the European League Against Rheumatism (EULAR) 2017 congress aimed to provide insights into the burden of psoriatic arthritis (PsA) on patients’ daily lives, including the significant impact of unresolved musculoskeletal symptoms, and explore the current guidelines for treatment, with a view to identifying strategies to optimise disease management. Case studies were used to evaluate current strategies in PsA management and highlight the critical role of the rheumatologist in patient care. The presentations emphasised that, while patient and clinician priorities for the management of PsA may differ, wider reporting of patient perspectives in studies and patient education may aid in aligning priorities and ensuring the best quality of life (QoL) for patients. The importance of tailoring treatment to the individual was reinforced, and the need to take into account all aspects of disease, including comorbidities and patient relevant outcomes, highlighted.